Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announces participation in the Tenth Annual Susquehanna Technology Conference from March 9-11, 2021. Due to Covid-19, the event will be virtual. The Company is gaining traction with its high-frequency XBAW® RF filters, expanding its product line to include filters for 5G and WiFi 6 markets. They plan to scale production capacity at their New York facility in response to a growing backlog. Akoustis has added 15 new filters to its catalog, targeting both commercial and defense sectors, while pursuing advancements in next-gen materials and semiconductor manufacturing.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a design win and volume order for its 3.6 GHz XBAW® filter solution aimed at last-mile connectivity, targeting network operators. The customer anticipates ramping production in the second half of 2021. This order follows significant interest in Akoustis' XBAW® filter portfolio post-CBRS auctions, which provided new spectrum for cellular carriers. The company also revealed a 500% capacity expansion plan for its New York facility to meet anticipated demand and recently added 15 new filters to its catalog for various market applications, including 5G and WiFi 6E.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a non-brokered registered direct offering, raising approximately $21.5 million by selling 1.5 million shares at $14.36 each, set to close today. Additionally, the company secured about $14.1 million through at-the-market offerings. The total gross proceeds from both offerings amount to roughly $35.6 million. Akoustis plans a 500% capacity expansion at its New York facility to meet demand for 5G and WiFi 6E applications, further doubling its manufacturing capacity. Fifteen new filters have been added to its product catalog, targeting various wireless markets.
Akoustis Technologies has announced the development of a new wafer-level-chip-scale-packaging (WLCSP) for its XBAW® RF filters, designed for 5G mobile devices and infrastructure. This packaging solution, which aligns with the industry's demand for smaller components, will be fully manufactured in North America. The first WLCSP device is anticipated to be qualified by the end of Q1 2021, with production expected to begin in June 2021. This innovation aims to unlock new market opportunities and enhance Akoustis' position in the growing RF filter industry.
Akoustis Technologies (AKTS) reported a 30% revenue increase above guidance, driven by demand across 5G mobile, WiFi, and infrastructure markets. The company plans to double manufacturing capacity by the end of 2021 to meet expected demand. In the December quarter, revenue reached $1.308 million, though losses increased to $11.91 million. Key highlights include new customer orders for XBAW filters, achieving design-lock on WiFi 6E filters, and a growing backlog of RF products. Akoustis continues to drive strategic milestones amid market expansion.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a volume order for its XBAW WiFi 6E RF filters from a tier-1 customer. The filters will support a new MU-MIMO router targeting the consumer market, expected to enter production in the second half of 2021. The company’s XBAW filters cover critical frequency bands from 5.1 to 7.1 GHz, facilitating robust performance in WiFi 6E applications. With increasing demand for high-performance filters, Akoustis anticipates significant revenue growth. The FCC's recent approval of new frequency bands is a pivotal development for the WiFi 6E market.
Akoustis Technologies (NASDAQ: AKTS) has announced the design-lock of its new 5.5 GHz and 6.5 GHz WiFi 6E XBAW filters, aimed at enhancing wireless connectivity. These filters, covering the UNII 1-3 and UNII 5-8 bands, promise low power loss and improved coexistence with existing frequencies. Expected to be qualified by early 2021 and in production by the end of Q2, Akoustis seeks to capitalize on the growing WiFi 6E market. The FCC's approval of additional spectrum for unlicensed use further supports this expansion. CEO Jeff Shealy emphasizes the potential for significant growth in revenue and unit sales.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced a redemption notice for its $15 million outstanding 6.5% Convertible Senior Secured Notes due March 2021. Holders can redeem notes for 100% of principal plus accrued interest or convert to common stock at a rate of 200 shares per $1,000. CEO Jeff Shealy stated this move aims to strengthen the company’s balance sheet by eliminating convertible debt, enhancing financial stability. The details are available in a recent SEC filing, and this announcement does not constitute a securities offer.
Akoustis Technologies (AKTS) will host an investor update call on February 1, 2021, at 8:00 a.m. ET to provide a business update and outlook. The company specializes in patented bulk acoustic wave (BAW) RF filters for wireless applications and has seen increased demand for its products. In 2020, Akoustis entered production across multiple markets, including 5G infrastructure and high-band WiFi. The call will include a question-and-answer session for investors. For audio participation, dial 877-407-3982 domestically or 201-493-6780 internationally.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced participation in the 23rd Annual Needham Virtual Growth Conference on January 11, 2021. Due to Covid-19 precautions, the event will be held virtually. Investors interested in meetings with Akoustis management should contact their Needham representative or Akoustis’ investor relations at ir@akoustis.com. The company is experiencing growing demand for its XBAW® filters, having launched 15 new products targeting 5G infrastructure, high-band WiFi, and defense markets throughout 2020.